Ireland - English - HPRA (Health Products Regulatory Authority)

hcs bvba - naproxen sodium - film coated tablet - 550 milligram - propionic acid derivatives

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

denk pharma gmbh & co. kg - fluconazole - capsules - 100mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

denk pharma gmbh & co. kg - fluconazole - capsules - 150mg

Ireland - English - HPRA (Health Products Regulatory Authority)

krka d.d., novo mesto - naproxen sodium - film-coated tablet - 550 milligram(s) - propionic acid derivatives; naproxen

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

denk pharma gmbh & co. kg - fluconazole - capsules hard - 100mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

genomma lab colombia ltda. - acetaminofÉn - acetaminofÉn....250.00 mg / cafeÍna anhidra....65.00 mg / naproxeno (sodico)....220.00 mg

United States - English - NLM (National Library of Medicine)

trigen laboratories, llc - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 20 mg

United States - English - NLM (National Library of Medicine)

palmetto pharmaceuticals - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 125 mg in 5 ml - naproxen oral suspension is indicated for: the relief of the signs and symptoms of: the management of: naproxen oral suspension is contraindicated in the following patients: risk summary: use of nsaids, including naproxen oral suspension, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including naproxen oral suspension, in pregnant women starting at 30 weeks of gestation (third trimester). there are no adequate and well-controlled studies of naproxen oral suspension in pregnant women. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2-4% for major malformations, and 15-20% for pregnancy loss. in animal reproduction studies in rats, rabbits, and mice no evidence of teratogenicity or fetal harm wh

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen oral suspension is indicated for: the relief of the signs and symptoms of: the management of: naproxen oral suspension is contraindicated in the following patients: risk summary use of nsaids, including naproxen oral suspension, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. because of these risks, limit dose and duration of naproxen oral suspension use between about 20 and 30 weeks of gestation, and avoid naproxen oral suspension use at about 30 weeks of gestation and later in pregnancy (see clinical considerations, data ). premature closure of fetal ductus arteriosus use of nsaids, including naproxen oral suspension , at about 30 weeks gestation or later in pregnancy increases the risk of premature closure of the fetal ductus arteriosus. oligohydramnios/neonatal renal impairment use of nsaids at about 20 weeks gestation or later in pregnancy has been associated with cases of fetal ren

United States - English - NLM (National Library of Medicine)

novitium pharma llc - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen oral suspension is indicated for: the relief of the signs and symptoms of: - rheumatoid arthritis - osteoarthritis - ankylosing spondylitis - polyarticular juvenile idiopathic arthritis - tendonitis - bursitis - acute gout the management of:  - pain. - primary dysmenorrhea naproxen oral suspension is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [see warnings and precautions (5.7,5.9)] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7,5.8)] - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1 cardiovascular thrombotic events)] risk summary use of nsaids, including naproxen oral suspension, can cause premature closure of the fetal ductus arteriosus a